Viewing Study NCT06932068


Ignite Creation Date: 2025-12-24 @ 5:33 PM
Ignite Modification Date: 2026-01-01 @ 1:54 PM
Study NCT ID: NCT06932068
Status: RECRUITING
Last Update Posted: 2025-04-17
First Post: 2025-04-10
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Phase II Trial of Iparomlimab/Tuvonralimab (QL1706) + XELOX in HER2-Negative, Low PD-L1 G/GEJ Adenocarcinoma
Sponsor: Qilu Hospital of Shandong University
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module